AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02942277 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menactra
Description: Menactra is FDA approved for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (but does not protect against serotype B) for use in individuals 9 months through 55 years of age
Study NCT02942277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
Study NCT02942277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
Study NCT02942277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coartem
Description: Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
Study NCT02942277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem
Description: Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
Study NCT02043288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15
Study NCT03907696 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anti-stigma interventions curriculum
Description: educational curriculum aimed at reducing stigma
Study NCT02575417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conversation Game
Description: The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
Study NCT02174224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
Study NCT02174224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management
Description: Case management based on needs-assessment. Resource connection and mentoring.
Study NCT02174224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Medical Care
Description: This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
Study NCT02584283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual hypothermic oxygenated perfusion
Description: Dual hypothermic oxygenated perfusion using the Liver Assist
Study NCT02584283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Liver Assist®
Description: The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
Study NCT02584283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perfusion fluid
Description: The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
Study NCT02584283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
Study NCT02661230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COGNIPLUS
Description: Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.~Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Study NCT00232557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLC-Asthma
Description: Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
Study NCT00232557 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TLC-health education
Description: A telephone-linked communication system (TLC) to provide general health education.
Study NCT02571140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: subcutaneous standard injection
Study NCT02571140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PTH (1-34)
Description: Different optimization of API
Study NCT00580957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blocked
Description: Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
Study NCT00580957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intact
Description: Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
Study NCT01783743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TT Training Program and TT Screening Card
Description: The intervention is an additional half day training program on trichiasis recognition (TT Training Program) and a TT Screening card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
Study NCT01607593 — intervention group
Intervention type: DRUG
Intervention: sertraline (Zoloft)
Description: Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
Study NCT03273959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
Study NCT01676493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine
Study NCT03572673 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexima 3S
Description: Flexima 3S (2-piece appliance) with drainable pouch
Study NCT03572673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New 2-piece ostomy appliance
Description: New 2-piece ostomy appliance with drainable pouch
Study NCT02842047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop, Breathe & Think™
Description: online daily meditations delivered using smart phone or other computer based application
Study NCT02842047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stop, Breathe & Think™
Description: online daily meditations delivered using smart phone or other computer based application
Study NCT02842047 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End of Life Planning Videos
Description: Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
Study NCT02842047 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiver wellness videos
Description: Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
Study NCT01368510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered daily 5 days/week for 4 weeks
Study NCT01368510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Cognitive Behavioral Therapy (CBT)
Description: Nondrug psychotherapy administered daily 5 days/week for 4 weeks
Study NCT01368510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Minimal contact waitlist weekly for 4 weeks
Study NCT00619788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4.0-5.0mm AngioSculpt Scoring Balloon Catheter
Description: The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
Study NCT03561896 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGRT
Description: Image-Guided Radiation Therapy
Study NCT03561896 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS
Description: stereotactic radiation therapy
Study NCT04102293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NSK Endo motor Endomate
Description: Rotary instrumenation used in pulp therapy
Study NCT01899898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified Modified Atkins Diet
Description: Modified Atkins diet with the following modifications:~1. Pictorial representation of various food items and exchange lists will be provided.~2. Instead of weights, we will provide standardized measures~3. We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures~4. We will formulate recipes and diets based on locally available and culturally acceptable foods.~5. We will develop a parent instruction manual.~6. We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.~7. We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes.
Study NCT01899898 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiepileptic drugs alone
Description: The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
Study NCT02499939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Education and home exercises
Study NCT02499939 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Education and home exercises
Study NCT04591626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC
Study NCT02499939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy
Description: Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.~(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)
Study NCT02559427 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-week immediate SPA treatment
Description: a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
Study NCT02559427 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 3-week late SPA treatment
Description: a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
Study NCT03043703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirSense 10 AutoSet for Her
Description: Positive airway pressure
Study NCT00330252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
Study NCT00330252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
Study NCT04709289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid, photodynamic therapy
Description: Aminolevulinic acid, photodynamic therapy
Study NCT00709228 — intervention group
Intervention type: DRUG
Intervention: PegIntron
Description: 1.5 ug/kg/week
Study NCT00709228 — intervention group
Intervention type: DRUG
Intervention: Rebetol
Description: 800-1200 mg/day
Study NCT02754063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PbtO2 probes
Description: PbtO2/ICP/CPP-directed therapy according to international recommendations
Study NCT05111470 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm throws with his dominant arm
Description: Seated patient with different sensors on his naked torso. Patients will throw a ball with their dominant arm. The trajectories will be recorded by Vicon MX-40
Study NCT02754063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No PbtO2 probes
Description: ICP/CPP-directed therapy according to international recommendations
Study NCT01499303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Phase II Trial to evaluate the efficacy of 200mg fostamatinib
Study NCT04909398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dynamic pupillometry sessions
Description: The evaluation protocol will include the following steps:~* Installation of the subject, adaptation of the chin rest for the best comfort of the participant~* Calibration of the oculometer consisting of ocular fixation of 9 fixation points distributed on the stimulation screen~* Final validation of the eligibility of the subject in the study according to the success or not of the calibration.
Study NCT01037556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
Study NCT01940939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
Study NCT01940939 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The MagPro X100 is connected to a Magnetic Coil which transfers the magnetic stimulation to the tissue. The original coils MC-B65 can be used with the MagPro X100.
Study NCT02589275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL Tablet 2.8 mg
Description: TNX-102 SL 2.8 mg tablet taken daily at bedtime
Study NCT01042366 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination
Description: Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
Study NCT01972022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EES SYNERGY™
Description: percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
Study NCT01972022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZES, RESOLUTE Integrity™
Description: percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
Study NCT04325074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice
Description: During each of the 12 treatment sessions, the patient was asked to select two tasks from a list of MP activities, graded by level. Once the task was selected, patients received the specific visual or audio instructions and subsequently performed the task. The recording was viewed three times and the audio instructions were repeated two times. To listen to the audio instructions, the participants were requested to close their eyes in order to aid concentration. After listening to the recordings, the patient was asked to perform the task once again, practicing what had been learnt. After the process was completed, the participant completed a questionnaire and scored each task.
Study NCT04325074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental practice + skill training
Description: In this option, six sessions of MP were alternated with six sessions of skills training (ST). The MP protocol was the same as in group A: selecting, performing, visualizing, listening to and scoring the selected tasks. The activities performed in the skills training were based on the Kamm et al. (2015) protocol and bimanual tasks. After the performance of each task, the patients were allowed to rest for 1 or 2 minutes to avoid the appearance of fatigue.
Study NCT04325074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group only received their usual physical therapy and occupational therapy treatments provided by their association. The treatment mainly consisted of the application of the Bobath concept and the Vojta method, dry needling, myofascial induction therapy, passive mobilizations, training of gross and fine motor coordination of the upper limbs, resistance training and static and dynamic balance training.
Study NCT00965653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid
Description: >/= 5 mg po weekly
Study NCT00965653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: >/= 5 mg po weekly
Study NCT00965653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 7.5 - 25 mg weekly (oral or parenteral)
Study NCT00965653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: 7.5 - 25 mg weekly (oral or parenteral)
Study NCT00965653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg sc weekly (QW)for 12 weeks
Study NCT00965653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab [RoActemra/Actemra]
Description: 162 mg sc every other week (Q2W) for 12 weeks
Study NCT02188797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group MI risk reduction program
Study NCT03665103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser-assisted ICSI
Description: Laser opening of the zona pellucida.
Study NCT02895529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters \[mL\]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
Study NCT02895529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.